Latest Stocks: Merus Labs International Inc (MSLI) Forecasted to Earn FY2018 Earnings of $0.02 Per Share

Latest Stocks: Merus Labs International Inc (MSLI) Forecasted to Earn FY2018 Earnings of $0.02 Per Share

Shares of Merus Labs International (NASDAQ:MSLI) traded down 0.85% during midday trading on Monday, hitting $1.17. 29,505 shares of the company were exchanged. The company has a 50-day moving average price of $0.86 and a 200-day moving average price of $0.87. The stock’s market capitalization is $137.29 million. Merus Labs International has a 52-week low of $0.70 and a 52-week high of $1.45. Merus Labs International (NASDAQ:MSLI) last announced its quarterly earnings data on Tuesday, February 14th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.02) by $0.02. Merus Labs International had a negative net margin of 10.36% and a negative return on equity of 3.94%. The firm had revenue of $19.53 million during the quarter, compared to analysts’ expectations of $23.18 million.

Merus Labs International Inc (NASDAQ:MSLI) (TSE:MSL) – Stock analysts at Clarus Securities issued their FY2018 earnings per share (EPS) estimates for shares of Merus Labs International in a research report issued to clients and investors on Friday. Clarus Securities analyst K. Cheung expects that the company will post earnings of $0.02 per share for the year.

Hedge funds have recently modified their holdings of the company. TD Asset Management Inc. boosted its stake in shares of Merus Labs International by 7.9% in the first quarter. TD Asset Management Inc. now owns 292,527 shares of the company’s stock worth $272,000 after buying an additional 21,507 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Merus Labs International by 3.0% in the first quarter. Acadian Asset Management LLC now owns 4,436,536 shares of the company’s stock worth $4,125,000 after buying an additional 127,530 shares during the last quarter. Finally, K.J. Harrison & Partners Inc purchased a new stake in shares of Merus Labs International during the first quarter worth about $190,000. Institutional investors and hedge funds own 23.09% of the company’s stock. Merus Labs International Company Profile

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.

Related posts

Leave a Comment